MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 251,659 shares of the company’s stock, valued at approximately $9,035,000.
A number of other institutional investors and hedge funds have also made changes to their positions in AMPH. Allspring Global Investments Holdings LLC acquired a new position in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $5,868,000. State of New Jersey Common Pension Fund D acquired a new position in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $907,000. Yousif Capital Management LLC acquired a new position in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $830,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Amphastar Pharmaceuticals by 89.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,710 shares of the company’s stock valued at $156,000 after purchasing an additional 3,161 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its holdings in Amphastar Pharmaceuticals by 2.7% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 15,300 shares of the company’s stock valued at $351,000 after purchasing an additional 400 shares in the last quarter. 59.79% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Amphastar Pharmaceuticals
In related news, CFO William J. Peters sold 5,512 shares of the business’s stock in a transaction that occurred on Friday, June 17th. The stock was sold at an average price of $32.05, for a total transaction of $176,659.60. Following the completion of the transaction, the chief financial officer now owns 100,480 shares in the company, valued at approximately $3,220,384. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 10,291 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, May 16th. The stock was sold at an average price of $35.61, for a total transaction of $366,462.51. Following the sale, the director now owns 47,206 shares of the company’s stock, valued at approximately $1,681,005.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 5,512 shares of Amphastar Pharmaceuticals stock in a transaction on Friday, June 17th. The shares were sold at an average price of $32.05, for a total value of $176,659.60. Following the sale, the chief financial officer now directly owns 100,480 shares in the company, valued at approximately $3,220,384. The disclosure for this sale can be found here. In the last quarter, insiders sold 148,641 shares of company stock worth $5,187,590. 27.80% of the stock is currently owned by corporate insiders.
Amphastar Pharmaceuticals Trading Down 0.5 %
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14. Amphastar Pharmaceuticals had a return on equity of 17.35% and a net margin of 17.87%. The firm had revenue of $120.37 million during the quarter, compared to analyst estimates of $110.60 million. During the same quarter last year, the firm earned $0.27 EPS. On average, equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 1.46 EPS for the current year.
Analyst Upgrades and Downgrades
AMPH has been the subject of a number of research reports. Capital One Financial assumed coverage on Amphastar Pharmaceuticals in a research note on Friday, July 29th. They issued an “overweight” rating and a $44.00 price objective for the company. Northland Securities increased their price objective on Amphastar Pharmaceuticals from $33.00 to $43.00 in a research report on Monday, April 11th. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $38.50.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.
- Get a free copy of the StockNews.com research report on Amphastar Pharmaceuticals (AMPH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.